Assenagon Asset Management S.A. acquired a new position in shares of Sientra Inc (NASDAQ:SIEN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 280,272 shares of the medical instruments supplier’s stock, valued at approximately $1,816,000. Assenagon Asset Management S.A. owned 0.57% of Sientra as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Point72 Hong Kong Ltd increased its position in shares of Sientra by 282.5% during the second quarter. Point72 Hong Kong Ltd now owns 3,997 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 2,952 shares during the period. NumerixS Investment Technologies Inc acquired a new stake in shares of Sientra during the second quarter worth $59,000. Private Advisor Group LLC acquired a new stake in shares of Sientra during the second quarter worth $62,000. Bailard Inc. increased its position in shares of Sientra by 28.9% during the second quarter. Bailard Inc. now owns 25,000 shares of the medical instruments supplier’s stock worth $154,000 after buying an additional 5,600 shares during the period. Finally, Ardsley Advisory Partners LP acquired a new stake in shares of Sientra during the second quarter worth $166,000. Institutional investors own 88.91% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, October 10th. Stephens set a $16.00 price objective on shares of Sientra and gave the stock a “buy” rating in a research report on Friday, August 9th. Craig Hallum decreased their price objective on shares of Sientra from $20.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Zacks Investment Research cut shares of Sientra from a “hold” rating to a “sell” rating in a research report on Friday, October 11th. Finally, ValuEngine upgraded shares of Sientra from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $15.75.
Sientra (NASDAQ:SIEN) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.50). The company had revenue of $20.53 million for the quarter, compared to the consensus estimate of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The firm’s revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.73) earnings per share. On average, equities analysts predict that Sientra Inc will post -2.42 earnings per share for the current year.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: Understanding the two types of arbitrage
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.